Last reviewed · How we verify
Adalimumab European source
Tumour necrosis factor-alpha inhibitor
Tumour necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
At a glance
| Generic name | Adalimumab European source |
|---|---|
| Sponsor | Synermore Biologics Co., Ltd. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that selectively binds to human tumour necrosis factor-alpha (TNF-alpha) and inhibits its interaction with cell surface TNF receptors. This action prevents the downstream effects of TNF-alpha, including inflammation and cytotoxicity.
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab European source CI brief — competitive landscape report
- Adalimumab European source updates RSS · CI watch RSS
- Synermore Biologics Co., Ltd. portfolio CI